Pre-operative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage nonsmall cell lung cancer Several randomised controlled trials and meta-analyses have shown that adding adjuvant cisplatin-based chemotherapy to surgical resection improves disease-free survival and overall survival in patients with early-stage nonsmall cell lung cancer (NSCLC). Compliance with post-operative chemotherapy is far from optimal, leading to incomplete treatment in many patients. Delivery of pre-operative or neoadjuvant chemotherapy was more feasible in several trials, but has been studied far less extensively than adjuvant therapy. This study reports the results of a phase III trial comparing pre-operative chemotherapy plus surgery, surgery plus adjuvant chemotherapy, or surgery alone in resectable NSCLC.
Patients and methods
A total of 624 patients with resectable earlystage NSCLC (stages IA .2 cm, IB, II or T3N1) were randomly assigned to surgery alone (212 patients), three cycles of pre-operative carboplatinpaclitaxel (CP) followed by surgery (201 patients) or surgery followed by three cycles of adjuvant CP (211 patients). The primary end-point was disease-free survival (DFS), secondary objectives were overall survival, and the assessment of chemotherapy delivery and adverse events.
Results
In the pre-operative arm, 97% of patients started the planned chemotherapy, 90% completed all three planned cycles, 9% had dose reductions at some point and 11% required one or more dose delays. Radiological response rate was 53%. In the adjuvant arm, 66% of the patients were able to start chemotherapy, only 61% received three cycles, 11% had at least one dose reduction and 16% required one or more dose delays.
94% of the patients underwent surgery: 95% in the surgery arm, 91% in the neoadjuvant arm and 96% in the adjuvant arm.
Surgical procedures and post-operative mortality were similar across the three arms.
Patients in the pre-operative arm had a nonsignificant trend toward longer DFS than those assigned to surgery alone (5-yr DFS 38% versus 34%; hazard ratio (HR) 0.92; p50.176). 5-yr DFS rates were 37% in the adjuvant arm versus 34% in the surgery arm (HR 0.96; p50.74).
Subgroup analyses (stage II-T3N1) showed 5-yr DFS rates of 25%, 37% and 31% in the surgery-alone group, the pre-operative group and the adjuvant group, respectively. 5-yr overall survival rates were 44%, 47% and 46%, respectively. For the stage II-T3N1 subgroup, they were 35%, 41% and 37%, respectively.
Conclusion
In early-stage patients, no statistically significant differences in DFS were found with the addition of pre-operative or adjuvant chemotherapy to surgery. In this trial, in which the treatment decision was made before surgery, more patients were able to receive pre-operative than adjuvant treatment.
Message
In patients with operable NSCLC, delivery of pre-operative chemotherapy is better tolerated and delivered than adjuvant chemotherapy.
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